Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Forte Biosciences, Inc. (NASDAQ: FBRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Forte is a clinical-stage biopharmaceutical company focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases, and its filings document key financial, clinical and corporate developments around this program.
Through forms such as 10-Q and 8-K, Forte reports its quarterly financial results, including research and development expenses tied to FB102 clinical and manufacturing activities, general and administrative costs, and net loss figures. Current reports on Form 8-K also disclose material events such as positive phase 1b data in celiac disease, the initiation and status of clinical trials, and the filing of related investor presentations.
Forte’s filings further describe capital markets transactions, including an underwriting agreement for a public offering of common stock and pre-funded warrants. In these documents, the company outlines the number of shares and pre-funded warrants offered, expected gross and net proceeds, use of proceeds for working capital and FB102 development, and the terms and limitations associated with the pre-funded warrants.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the main points from lengthy documents, helping readers quickly understand the implications of Forte’s 10-Qs, 8-Ks and other filings. Real-time updates from the EDGAR system, along with organized access to financial reports and material event disclosures, allow investors and researchers to review Forte Biosciences’ regulatory history and ongoing obligations as a Nasdaq-listed, clinical-stage biopharmaceutical company.
Forte Biosciences (FBRX) announced a public offering of 5,630,450 shares of common stock at $12.00 per share and 619,606 pre-funded warrants at $11.999 per warrant. The total offering value is approximately $75 million, with net proceeds of $70.5 million after underwriting discounts.
Key offering details:
- Pre-funded warrants have $0.001 exercise price with no expiration
- Underwriters granted 30-day option to purchase additional 937,508 shares
- Joint book-runners: TD Cowen, Evercore ISI, Guggenheim Securities, and Chardan
The company recently reported positive Phase 1b trial results for FB102 in celiac disease, showing: statistically significant benefits in VCIEL endpoint (p=0.0099), 73% improvement in Vh:Cd ratio, and 42% reduction in GI symptoms versus placebo. FB102 is an anti-CD122 monoclonal antibody targeting autoimmune conditions, currently in trials for celiac disease and vitiligo.
Forte Biosciences (NASDAQ:FBRX) announced a significant public offering of common stock and pre-funded warrants. The company plans to issue 5,630,450 shares at $12.00 per share and 619,606 pre-funded warrants at $11.999 per warrant. The offering, expected to close around June 26, 2025, will generate approximately $75.0 million in gross proceeds (potentially $80.5 million if underwriters exercise their option). Net proceeds of approximately $70.0 million are expected to fund operations into 2027. The offering is being managed by TD Securities, Evercore, Guggenheim Securities, and Chardan Capital Markets.
Forte Biosciences, Inc. (Nasdaq: FBRX) has filed a preliminary prospectus supplement (Form 424B5) for a public offering of common stock and pre-funded warrants. Exact share count, pricing, and gross proceeds are still blank placeholders, indicating terms will be set immediately prior to pricing. Investors may elect pre-funded warrants, each exercisable for one common share at a nominal $0.001 exercise price and with no expiration, in lieu of common shares.
The offering is being made off the company’s effective Form S-3 shelf (File No. 333-286226) dated 3 April 2025. Joint book-running managers are TD Cowen, Evercore ISI, Guggenheim Securities and Chardan, with Lucid Capital Markets acting as co-manager. Underwriters hold a 30-day option to purchase an additional allotment of common shares (greenshoe) at the public offering price, less underwriting discounts and commissions.
Use of proceeds, dilution calculations, and updated risk factors will be detailed once terms are finalized. The filing reiterates Forte’s status as a “smaller reporting company,” allowing scaled disclosures. The company highlights its Phase 1 data for lead candidate FB102, an anti-CD122 monoclonal antibody targeting autoimmune indications, and states that prior NHP and healthy-volunteer studies showed favorable safety and pharmacodynamic activity.
Key investor considerations:
- Dilution: The sale of new equity and perpetual pre-funded warrants will increase the share count once finalized.
- Capital needs: Forte remains a clinical-stage company with no commercial revenue and will depend on financing to advance FB102 into further trials.
- Market reception: Last reported share price (23 June 2025) was $12.76; pricing below market would signal near-term pressure, whereas in-line pricing may limit dilution impact.
- Liquidity of warrants: Pre-funded warrants will not be listed on Nasdaq, limiting secondary-market liquidity for warrant holders.
Absent final terms, investors should monitor the subsequent free-writing prospectus or final supplement for precise pricing, proceeds, and dilution data before making investment decisions.